No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Percheron Therapeutics Submits Non-binding Licensing Proposal for Drug Development Program, Shares Jump 8%
Percheron Therapeutics Proposes to In-license New Drug Program for Rare Neurological Disease
Percheron Therapeutics Ltd: Letter From The Chair and Half Year Accounts
Percheron Therapeutics Expects Partnering Proposals This Month After Rapid Progress in Discussions | ASX:PER, OTC:PERCF
ASX Small-Cap Stocks to Watch
Percheron Therapeutics Regroups After Clinical Trial Results; Vows to Continue to Conserve Cash and Develop Pipeline | ASX:PER, OTC:PERCF